HealthDay News — Treatments other than statins also can effectively reduce cardiovascular (CV) risk, according to a review and meta-analysis published in the JAMA.

Marc Sabatine, MD, MPH, a cardiologist at Brigham and Women’s Hospital in Boston, and colleagues analyzed the results of 49 clinical trials. These included 25 clinical trials for statins, as well as trials for heart-healthy diet, ezetimibe, bile acid sequestrants, and ileal bypass surgery. The evidence review also included two trials with PCSK9 inhibitors.

Non-statin therapies reduced CV risk by 25% for each 1-mmol/L decrease in LDL cholesterol levels. That was similar to the 23% reduction per 1-mmol/L decrease seen with statins like atorvastatin and simvastatin, the researchers said. Ezetimibe reduced cholesterol by about 20%, statins by 30% to 50% depending on dose, and PCSK9 inhibitors by as much as 60%, according to Dr Sabatine. But the different trials showed that each unit of LDL cholesterol removed from the bloodstream protects CV health, regardless of how.

Continue Reading

“There is a linear relationship between what your LDL cholesterol level is and what your risk is of CV events,” Dr Sabatine told HealthDay. “The relationship suggests that lower is better.” What’s more, the benefits of these therapies stack up if more than one proves effective at lowering a person’s cholesterol levels, he added. “The focus really should be not on a particular drug, but on reducing LDL cholesterol. These data show there are multiple interventions that can do that.”

Disclosures: Several researchers disclosed relationships with one or more of the following: Aegerion, Alnylam, Amarin, American College of Cardiology, Amgen, Anglemed, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Clinical Research Institute, Bristol-Myers Squibb, Celera, Cubist, CVS Caremark, Daiichi Sankyo, Eisai, Eli Lilly, Esperion Therapeutics, Genzyme, Gilead, GlaxoSmithKline, ICON Clinical, Intarcia, Ionis Therapeutics, Janssen, Lexicon, MedImmune, Menarini International, Merck, MyoKardia, Novartis, Pfizer, Portola, Poxel, Quest Diagnostics, Regeneron, Roche Diagnostics, Sanofi-Aventis, St. Jude, Stealth Peptides, Takeda, The Medicines Company, Theravance, and Zeus Scientific.

Related Articles


  1. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA. 2016;316(12):1289-1297. doi:10.1001/jama.2016.13985.